nference company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$60M | 1 yr ago

About nference

nference offers a platform that enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference makes biomedical knowledge computable and builds its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

nference Headquarter Location

One Main Street, Suite 400 East Arcade, 4th Floor

Cambridge, Massachusetts, 02142,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing nference

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

nference is included in 7 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.


Digital Health

12,812 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

2,246 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

nference Patents

nference has filed 8 patents.

The 3 most popular patent topics include:

  • Computational linguistics
  • Natural language processing
  • Data management
patents chart

Application Date

Grant Date


Related Topics




Natural language processing, Computational linguistics, Knowledge representation, Data management, Semantic Web


Application Date


Grant Date



Related Topics

Natural language processing, Computational linguistics, Knowledge representation, Data management, Semantic Web



Latest nference News

nference Accelerates Self-Supervised Language Model Training with Cerebras CS-2 System

Mar 14, 2022

The ability to harness vast amounts of health data using advanced AI technology will lead to new discoveries and insights needed to improve patient care March 14, 2022 09:00 AM Eastern Daylight Time SUNNYVALE, Calif.--( BUSINESS WIRE )-- Cerebras Systems , the pioneer in high performance artificial intelligence (AI) compute, and nference , an AI-driven health technology company, today announced a collaboration to accelerate natural language processing (NLP) for biomedical research and development by orders of magnitude with a Cerebras CS-2 system installed at the nference headquarters in Cambridge, Mass. The vast amounts of health data that lie within patient records, scientific papers, medical imagery, and genomic databases could be critical to advancing health outcomes. Unfortunately, this information is nearly impossible for data scientists and machine learning (ML) researchers to access, as it exists in unstructured, siloed, and incompatible forms, forcing researchers to sift through it manually. While data accessibility is a fundamental challenge in healthcare today, newer AI architectures such as transformer models can assist by processing data from various sources, de-identifying it, and converting it into structured, usable intelligence. nference uses transformer AI models to employ self-supervised learning from large volumes of unstructured data without labels, translating vast amounts of health data into information that can be used to discover insights and drive research. However, training large models is complex, computationally intensive, and time-consuming, often requiring large clusters of conventional processors. A key feature of the Cerebras CS-2 architecture is the ability for data scientists and ML researchers to use data of longer sequence lengths than is practical using smaller, conventional processors – this is particularly relevant to research being conducted at nference. “nference was founded to help solve complex medical problems and improve health outcomes by unlocking insights contained within biomedical data while protecting individual patient privacy,” said Ajit Rajasekharan, Chief Technology Officer, nference. “Our solution uses transformer models to help researchers and clinicians make sense of siloed and inaccessible health data, leading to new discoveries and findings that can impact patient outcomes. With Cerebras’s powerful CS-2 system, we can train transformer models with much longer sequence lengths than we could before, enabling us to iterate more rapidly and build better, more insightful models.” “AI is driving an exponential increase in demand for compute,” said Andy Hock, Vice President of Product, Cerebras Systems. “As we have recently demonstrated across multiple customers and published work, the Cerebras CS-2 is orders of magnitude faster than legacy alternatives. This orders-of-magnitude performance advantage comes from the Cerebras Wafer Scale Engine (WSE-2), the world’s largest and most powerful AI processor. The WSE-2 is purpose built with 850,000 AI-optimized cores to accelerate the models of today and unlock future models not practical or possible on legacy infrastructure. The partnership and our work with nference is a great example of this, where their team – equipped with a CS-2 – is pushing the boundaries of AI to accelerate biomedical research and discovery to improve health outcomes.” The Cerebras CS-2 system delivers the deep learning compute performance of hundreds of graphics processing units in a cluster, with the programming ease and efficiency of a single system. Powered by the largest and fastest processor ever built – the 2.6 trillion transistor second-generation Cerebras Wafer-Scale Engine (WSE-2) – the CS-2 delivers more AI-optimized compute cores, fast memory, and fabric bandwidth than any other deep learning processor in existence. A CS-2 delivers the wall-clock compute performance of many tens to hundreds of GPUs with the programming ease and efficiency of a single device. About Cerebras Systems Cerebras Systems is a team of pioneering computer architects, computer scientists, deep learning researchers, and engineers of all types. We have come together to build a new class of computer system, designed for the singular purpose of accelerating AI and changing the future of AI work forever. Our flagship product, the CS-2 system is powered by the world’s largest processor – the 850,000 core Cerebras WSE-2, enables customers to accelerate their deep learning work by orders of magnitude over graphics processing units.

nference Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

nference Rank

  • When was nference founded?

    nference was founded in 2013.

  • Where is nference's headquarters?

    nference's headquarters is located at One Main Street, Suite 400, Cambridge.

  • What is nference's latest funding round?

    nference's latest funding round is Series C.

  • How much did nference raise?

    nference raised a total of $143.6M.

  • Who are the investors of nference?

    Investors of nference include Matrix Partners, Mayo Clinic Ventures, NTT Venture Capital and Matrix Capital Management.

  • Who are nference's competitors?

    Competitors of nference include BenevolentAI, ConcertAI, Owkin, BioSymetrics, Causaly, Evidation, insitro, EvidScience, Tempus, Atomwise and 12 more.

You May Also Like

GNS Healthcare Logo
GNS Healthcare

GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.

Standigm Logo

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong developing a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties and generate synthetic data.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases


BERG is a Boston-based biopharma company focused on taking a bold "back to biology" approach to therapeutic discovery using its unique AI-based Interrogative Biology platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient's own biology drives the platform's results and guides the company in the discovery and development of drugs, diagnostics and healthcare applications. Its platform utilizes patient population health data to bring actionable Patient Intelligence to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.


Dezzai develops global, accessible, and transversal AI solutions that enhance the creation and exchange of knowledge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.